Literature DB >> 3300140

Diabetic retinopathy after 3 years' treatment with continuous subcutaneous insulin infusion (CSII).

T Olsen, B Richelsen, N Ehlers, H Beck-Nielsen.   

Abstract

Twenty-four insulin-dependent juvenile diabetics with no or minimal background retinopathy were randomly allocated to conventional insulin therapy (CIT) or continuous sc insulin infusion (CSII) administrated by a portable pump. At the present 3 year follow-up, there was one drop-out in the CSII group. Although the metabolic control was significantly better in the CSII patients, both groups improved significantly in metabolic control during the observation period. After 3 years, the HbA lc level was 7.4% +/- 1.2 (+/- SD) in the CSII patients and 8.6% +/- 1.6 in the CIT patients (P less than 0.01). As compared to the status at the beginning of the study, a progression of diabetic retinopathy (criteria: development of more than 2 microaneurysms) was observed in 4 of 11 in the CSII group and in 5 of 12 in the CIT group (P greater than 0.05). None of the patients were seen to develop soft exudates or neovascularisations. This study confirms the impression gained from a previous one-year follow-up of similar progression of retinopathy in patients on CSII and CIT.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3300140     DOI: 10.1111/j.1755-3768.1987.tb06998.x

Source DB:  PubMed          Journal:  Acta Ophthalmol (Copenh)        ISSN: 0001-639X


  4 in total

1.  Blood-retinal and blood-aqueous barrier permeability, lens autofluorescence and transmission in insulin-dependent diabetic youngsters.

Authors:  E van Wirdum; J van Best; G J Bruining; C de Beaufort; J Oosterhuis
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1989       Impact factor: 3.117

2.  Blood glucose concentrations and progression of diabetic retinopathy: the seven year results of the Oslo study.

Authors:  O Brinchmann-Hansen; K Dahl-Jørgensen; L Sandvik; K F Hanssen
Journal:  BMJ       Date:  1992-01-04

Review 3.  Results of the DCCT trial. Implications for managing our patients with diabetes.

Authors:  G Worrall
Journal:  Can Fam Physician       Date:  1994-11       Impact factor: 3.275

4.  Long-term comparison of human insulin analogue B10Asp and soluble human insulin in IDDM patients on a basal/bolus insulin regimen.

Authors:  F S Nielsen; L N Jørgensen; M Ipsen; A I Voldsgaard; H H Parving
Journal:  Diabetologia       Date:  1995-05       Impact factor: 10.122

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.